Dr. Tatyana Sergeyeva

Dr. Donner's clinical and research interests have focused on the prevention of complications in patients with type 1 and 2 diabetes. For 6 years, he was the Associate Medical Director of the Joslin Diabetes Center affiliate at the University of Maryland, and then Medical Director from 2004 - 2010. After joining the faculty at Johns Hopkins University in 2010, his clinical and research interests became fully dedicated to diabetes. He became the Director of The Johns Hopkins Diabetes Center in 2011. He has been a clinical investigator in a number of NIH- and industry-funded diabetes research trials. Dr. Donner was a co-PI in the NIH-funded Veterans Affairs Implantable Insulin Pump Study, a Co-PI on the NIDDK-funded Diabetes Control and Complications Trial / Epidemiology of Diabetes Intervention and Complications (DCCT / EDIC) Study for 16 years, and Co-PI for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) for 7 years. Recently, he has served as PI for the Durable-response therapy Evaluation For Early or New-onset type 1 Diabetes (DEFEND-1). Dr. Donner is currently collaborating with Dr. Abdel Hamad in Immunology on preventing B-regulatory cell apoptosis using a novel monoclonal antibody targeting the presumptive apoptotic factor. This antibody prevents the development of type 1 diabetes in non obese diabetic mice. Dr. Donner is the PI for Johns Hopkins for TrialNet, a multicenter, international consortium of investigators studying ways to prevent Type 1 diabetes and preserve insulin secretion in individuals with newly diagnosed Type 1 diabetes. He is also a PI for a study investigating FIAsp, a faster-acting insulin aspart in subjects with type 1 diabetes, and is working with investigators at the Johns Hopkins School of Engineering on an implantable insulin pump which delivers insulin intravenously. Dr. Donner is rated as an Advanced provider by MediFind in the treatment of Diabetic Nephropathy. His top areas of expertise are Type 1 Diabetes (T1D), Diabetic Nephropathy, Type 2 Diabetes (T2D), and Maturity Onset Diabetes of the Young.

Olufunmilayo Onobrakpeya is an Endocrinologist in Bel Air, Maryland. Dr. Onobrakpeya is rated as a Distinguished provider by MediFind in the treatment of Diabetic Nephropathy. Her top areas of expertise are Type 2 Diabetes (T2D), Diabetic Nephropathy, Thyroid Nodule, and Paget's Disease of Bone.

Prakash Seshadri is an Endocrinologist in Newark, Delaware. Dr. Seshadri has been practicing medicine for over 29 years and is rated as a Distinguished provider by MediFind in the treatment of Diabetic Nephropathy. His top areas of expertise are Type 2 Diabetes (T2D), Maturity Onset Diabetes of the Young, Hypothyroidism, and Type 1 Diabetes (T1D).